The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Phase 1TerminatedNCT01753674

University of Connecticut13 enrolled

Overview

Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.

This is double blind cross over randomized clinical trial. The supplement and placebo will be provided by TA Science, Inc. and prepared as described below. Subjects will be randomly allocated to consume either a daily serving of TA-65 (two capsules per day of 8 mg each) (please see attached label) or a placebo for 12 weeks. Randomization will be done in a sequential manner; the first subject will be allocated to supplement A and the next one to supplement B and so on. After a 3-week washout, they will be allocated to the alternate treatment for additional 12 weeks. Supplements (TA-65 or placebo) will be taken twice daily with a meal. Participants will be advised not to change their diet or exercise protocols during the 27 week intervention. Volunteers will be required to provide a 5-day dietary record before starting the study, at the end of each supplement period (TA-65 or placebo) and at the end of the washout period. Subjects will have to fill an exercise questionnaire during the same times to ensure that there are no changes in physical activity. Participants will be asked to report to the department every 4 weeks for checking compliance on supplement intake and to assess weight and blood pressure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Metabolic Syndrome Insulin Resistance

Interventions

TA-65DIETARY_SUPPLEMENT

TA-65 will be provided to volunteers, 2 pills per day of 8 mg each

PlaceboDIETARY_SUPPLEMENT

Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each

Eligibility

Sex: ALLMin age: 35 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: The inclusion criteria are: men and women (40-70 y) with metabolic syndrome which means having at least 3 of the following characteristics: * Blood pressure \> 130/85 mm Hg * plasma glucose \> 100 mg/dL * plasma triglycerides \> 150 mg/dL * HDL cholesterol \< 40 mg/dL (men) and \< 50 mg/dL (women) * waist circumference \>102 cm (men) and ≥ 88 cm (women) * Women of childbearing age should be using contraception Exclusion Criteria: Exclusion criteria will be * self-reported diabetes mellitus * coronary heart disease * triglycerides greater than 400 mg/dL * Fasting glucose greater than 126 mg/dL * Blood pressure greater than 140/100 mmg Hg * history of stroke * Use of alcohol at an elevated rate (more than two drinks per day) * Renal problems * liver disease * cancer * pregnancy and lactation * severe infectious diseases * autoimmune disease currently under treatment * current hormone therapy * previous treatment with TA-65. * Intake of glucose-lowering prescriptions * Use of immunosuppressants, lithium or supplements such as Sulphonylureas (Glucotrol, Amaryl), Thiazolidinedione (Avandia, ACTOS,), Meglitinides (Prandin, Starlix), Biguanides (Metformin), Alpha-glucosidase inhibitors (Precose, Glyset), dipeptidyl peptidase (DPP)-4 inhibitors (Januvia, Onglyza) * high dose chromium or cinnamon supplements * Consistent intake of vitamin, mineral, or multivitamin supplements prior to recruitment may be admitted into the study if they plan on maintaining their current supplement program. However, subjects may not participate if they begin taking a new supplement during the 27-wk study period. -Subjects will also be asked to refrain from taking any additional supplements, including fish oil, herb and concentrated antioxidant sources.

Locations (1)

University of Connecticut

Storrs, Connecticut, United States

Outcomes

Primary Outcomes

Plasma insulin levels

The supplement is anticipated to decrease insulin resistance in individuals with metabolic syndrome. The investigators will measure plasma insulin and plasma glucose as outcomes measures

Time frame: 27 weeks

Secondary Outcomes

plasma HDL cholesterol

It is expected that the TA-65 supplement will increase plasma HDL, another characteristic of metabolic syndrome

Time frame: 27 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.